AI screening tool using WhatsApp to predict genetic risk for breast cancer
Official title: Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer (STAR-BREAST)
Run by AstraZeneca · NCT07070128 · Data updated 2026-11-12
This project will test whether an AI-based WhatsApp virtual assistant can use family cancer history to predict which women referred for genetic evaluation have higher genetic risk for breast cancer.
Quick facts
| Study type | Observational |
|---|---|
| Sex | Women only |
| Enrollment | 800 (estimated) |
| Sponsor | AstraZeneca Industry-sponsored |
| Locations | 3 sites (Golania, Goiás and 2 other locations) |
| Status | Recruiting |
| Started | August 20, 2025 |
| Main results expected | August 11, 2026 |
| Study ends | August 11, 2026 |
| Registry record updated | July 29, 2026 |
| Trial ID | NCT07070128 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women aged 18 or older who were identified by breast surgeons as at high genetic risk, referred to a geneticist, have adequate medical records, and agree to participate.
✕Probably not a fit
Male patients, people lacking complete medical records, those who do not know their biological family history, or those not referred for genetic evaluation are unlikely to benefit from this effort.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This retrospective observational study will review medical records of women aged 18 and older, identified by breast specialists as at high genetic risk and referred to a geneticist, from 2017–2024. Eligible patients at two Brazilian centers will be asked to provide family cancer history via an AI virtual assistant developed by WeConecta on WhatsApp. The AI tool's risk predictions will be compared to documented genetic testing results and specialist evaluations. The coordinating site is the Breast Center at Hospital Moinhos de Vento in Porto Alegre, with supporting data from the Human Genetics Center (CEGH/ICB) at the Federal University of Goiás in Goiânia.
Why it matters
Potential benefit: If successful, this tool could speed up identification of women with hereditary breast cancer risk and help prioritize referrals to genetic services.
How similar studies have gone: Digital family-history collection tools and established risk models have shown promise for flagging high-risk individuals, but using an AI WhatsApp assistant specifically to predict genetic breast cancer risk is relatively new and not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * female patients, * aged 18 years or older, * identified as high genetic risk by breast surgeons, * referred to a geneticist, and * who agree to participate in the study. Exclusion Criteria: * male patients, * absence of complete information in the medical records, * patients unaware of their biological family history, and * patients who do not agree to participate in the study.
Where it's running
-
Research Site
Porto Alegre, Rio Grande do Sul, Brazil Recruiting -
Research Site
Golania, Goiás, Brazil Withdrawn -
Research Site
Porto Alegre, Rio Grande do Sul, Brazil Not yet recruiting
Study contacts
- Study coordinator: AstraZeneca Clinical Study Information Center
- Email: information.center@astrazeneca.com
- Phone: 1-877-240-9479
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Improved Facial Skin Quality After VYC-12L for Breast Cancer Survivors
This study tests whether intradermal injections of VYC-12L can improve facial skin quality and quality of life in adults who have completed breast cancer treatment.
-
Breast cancer subtypes and outcomes in Colombian women
This study looks back at medical records of women with breast cancer to see how different molecular subtypes relate to survival and recurrence in a single Colombian hospital.
-
Multimodal psychosomatic symptom care for breast cancer: personalized acupuncture care guided by shared decision-making
This study tests whether personalized acupuncture options (manual acupuncture, ear acupuncture, or both) can help women with breast cancer who have anxiety, sleep problems, or fatigue, compared to routine nursing care.
-
Slow Jogging for Breast Cancer Survivors
This study tests whether a 12-week slow jogging program helps sleep quality in women who have completed breast cancer treatment.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
Benchmarking AI language models against tumor boards for oncology treatment decisions
This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.